Skip to main content

Exelixis, Inc.

EXEL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000939767

In the last 90 days, Exelixis, Inc. insiders filed 0 open-market purchases and 1 sale; 760 institutions reported holding it in 13F filings for Q2 2026, worth $14.1B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Exelixis, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $526.5K in total
Insiders trading
1
Net value
−$526.5K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Exelixis, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Exelixis, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Beckerle Mary CDirector16,079Aug 12, 20264
Wyszomierski Jack LDirector284,384Jun 3, 20263
Eckhardt Sue GailDirector16,079Jun 3, 20263
Caligan Partners LPDirector, Other: See Remarks1,553,262IndirectMay 29, 20262
Johnson David EdwardDirector1,553,262IndirectMay 29, 20262
Poste GeorgeDirector127,199May 29, 20262
Papadopoulos SteliosDirector1,197,595May 29, 20262
Freire Maria CDirector109,186May 29, 20262
Smith JulieDirector28,957May 29, 20262
Oliver BobDirector29,487May 29, 20263
Heyman Tomas J.Director50,649May 29, 20261
Aftab DanaEVP, Research and Development594,741May 28, 202610
Haley Patrick J.EVP, Commercial357,638May 22, 20266
Morrissey MichaelPresident and CEO2,004,327IndirectMay 19, 20266
Senner Christopher J.EVP and CFO952,317May 19, 20264
Hefti BrendaSVP and General Counsel106,762May 19, 20264
Hessekiel JeffreyEVP & General Counsel693,396May 16, 20250
Peterson Amy C.EVP Prod Dev & Med Aff & CMO465,393May 16, 20250
Garber Alan MDirector35,703Mar 25, 20240
Wright JacquelineDirector51,756Jun 2, 20230
Goodman Vicki LEVP, Prod Dev & Med Aff &CMO307,654Apr 5, 20230
Feldbaum Carl BDirector18,701Feb 10, 20230
Lamb PeterEVP, Scientific Strategy & CSO410,958Dec 16, 20220
Marchesi Vincent TDirector93,989May 27, 20220
Willsey LanceDirector424,415May 27, 20220
Schwab GiselaPres, Prod Dev & Med Aff & CMO689,078Jul 28, 20210
Cohen CharlesDirector261,375Jul 8, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 16, 2021 (view filing)Jul 151 dayLamb PeterEVP, Scientific Strategy & CSOSSale−60.0K$17.47−$1.05M−13.3%389.5K after
Aug 18, 2021 (view filing)Aug 162 daysLamb PeterEVP, Scientific Strategy & CSOSSale−55.0K$18.44−$1.01M−12.4%389.5K after
Sep 17, 2021 (view filing)Sep 152 daysLamb PeterEVP, Scientific Strategy & CSOSSale−47.5K$20.46−$971.9K−10.9%389.5K after
Sep 17, 2021 (view filing)Sep 161 dayHaley Patrick J.EVP, CommercialSSale−25.0K$20.36−$509.0K−8.2%281.0K after
Oct 15, 2021 (view filing)Oct 15Same dayHessekiel JeffreyEVP and General CounselSSale−12.9K$22.02−$283.7K−2.0%637.9K after
Oct 15, 2021 (view filing)Oct 15Same dayLamb PeterEVP, Scientific Strategy & CSOSSale−47.5K$21.92−$1.04M−10.4%411.2K after
Nov 3, 2021 (view filing)Nov 12 daysHessekiel JeffreyEVP and General CounselSSale−5.12K$22.03−$112.7K−0.8%632.8K after
Nov 17, 2021 (view filing)Nov 152 daysLamb PeterEVP, Scientific Strategy & CSOSSale−47.5K$18.09−$859.3K−10.4%411.2K after
Nov 23, 2021 (view filing)Nov 194 daysFeldbaum Carl BDirectorSSale−20.0K$17.62−$352.4K−70.1%8.52K after
Nov 26, 2021 (view filing)Nov 242 daysHaley Patrick J.EVP, CommercialSSale−17.2K$17.25−$297.3K−6.8%237.8K after
Dec 17, 2021 (view filing)Dec 152 daysLamb PeterEVP, Scientific Strategy & CSOSSale−47.5K$17.44−$828.4K−11.6%363.2K after
Feb 4, 2022 (view filing)Feb 31 dayHaley Patrick J.EVP, CommercialSSale−60.0K$17.91−$1.07M−19.7%245.2K after
Feb 24, 2022 (view filing)Feb 222 daysFeldbaum Carl BDirectorSSale−20.0K$19.49−$389.8K−70.1%8.52K after
Feb 24, 2022 (view filing)Feb 222 daysPapadopoulos SteliosDirectorSSale−84.5K$19.56−$1.65M−6.5%1.22M after
Feb 28, 2022 (view filing)Feb 253 daysHaley Patrick J.EVP, CommercialSSale−31.2K$19.53−$610.1K−13.6%198.5K after
Feb 28, 2022 (view filing)Feb 244 daysHessekiel JeffreyEVP and General CounselSSale−18.0K$20.00−$360.0K−3.1%555.4K after
Mar 3, 2022 (view filing)Mar 12 daysGarber Alan MDirectorSSale−21.3K$21.00−$447.3K−40.4%31.4K after
Mar 30, 2022 (view filing)Mar 28-292 daysHessekiel JeffreyEVP, General Counsel & SecSSale−18.0K$22.00−$396.0K−2.9%605.2K after2 lots
Apr 4, 2022 (view filing)Mar 31-Apr 14 daysHaley Patrick J.EVP, CommercialSSale−20.0K$22.72−$454.3K−6.9%269.2K after2 lots
Apr 6, 2022 (view filing)Apr 42 daysWyszomierski Jack LDirectorSSale−6.70K$23.00−$154.0K−2.4%273.2K after
May 13, 2022 (view filing)May 121 dayWillsey LanceDirectorSSale−40.0K$19.65−$786.0K−8.6%424.4K after
Jun 1, 2022 (view filing)May 275 daysHaley Patrick J.EVP, CommercialSSale−18.8K$18.21−$342.6K−7.3%239.8K after
Sep 14, 2022 (view filing)Sep 122 daysHaley Patrick J.EVP, CommercialSSale−40.0K$17.94−$717.6K−13.3%261.6K after
Nov 17, 2022 (view filing)May 17, 2021-May 16, 2022549 daysLateHessekiel JeffreyEVP, General Counsel & SecSSale−36.0K$22.73−$818.3K−5.8%586.8K after2 lots
Dec 1, 2022 (view filing)Nov 292 daysPoste GeorgeDirectorSSale−40.0K$16.68−$667.2K−17.2%193.2K after
Dec 16, 2022 (view filing)Dec 151 dayLamb PeterEVP, Scientific Strategy & CSOSSale−20.0K$15.88−$317.6K−4.6%411.0K after
Feb 8, 2023 (view filing)Feb 62 daysHaley Patrick J.EVP, CommercialSSale−25.0K$17.37−$434.3K−8.9%254.4K after
Feb 10, 2023 (view filing)Feb 91 dayFeldbaum Carl BDirectorSSale−40.0K$17.78−$711.2K−68.1%18.7K after
Feb 23, 2023 (view filing)Feb 212 daysGarber Alan MDirectorSSale−40.0K$17.49−$699.6K−56.0%31.4K after
Mar 1, 2023 (view filing)Feb 27-282 daysAftab DanaCSO/EVP Disc & Trans ResearchSSale−82.5K$17.50−$1.44M−19.0%351.5K after2 lots
Mar 3, 2023 (view filing)Mar 12 daysHessekiel JeffreyEVP, General Counsel & SecSSale−77.9K$17.13−$1.33M−12.9%527.7K after
Mar 14, 2023 (view filing)Mar 104 daysWyszomierski Jack LDirectorSSale−15.3K$16.61−$254.1K−4.6%317.5K after
Apr 5, 2023 (view filing)Apr 5Same dayHessekiel JeffreyEVP, General Counsel & SecSSale−38.9K$20.01−$779.0K−6.3%582.4K after10b5-1
Aug 3, 2023 (view filing)Aug 12 daysHessekiel JeffreyEVP, General Counsel & SecSSale−55.7K$19.63−$1.09M−8.9%572.0K after10b5-1
Aug 7, 2023 (view filing)Aug 34 daysHaley Patrick J.EVP, CommercialSSale−30.6K$20.67−$631.5K−9.7%285.5K after
Aug 7, 2023 (view filing)Aug 3-44 daysSenner Christopher J.EVP and CFOSSale−120.0K$20.60−$2.47M−17.4%571.6K after2 lots
Sep 1, 2023 (view filing)Aug 302 daysAftab DanaCSO/EVP Disc & Trans ResearchSSale−4.60K$22.47−$103.4K−1.1%399.9K after10b5-1
Nov 29, 2023 (view filing)4:30 PM ETNov 272 daysCaligan Partners LP and 1 otherDirectorSSale−120.4K$21.61−$2.60M−13.2%790.3K after
Nov 29, 2023 (view filing)4:30 PM ETNov 272 daysCaligan Partners LP and 1 otherDirectorPPurchase+120.4K$21.61+$2.60M+15.2%910.7K after
Dec 4, 2023 (view filing)Nov 30-Dec 44 daysHessekiel JeffreyEVP, General Counsel & SecSSale−50.0K$22.04−$1.10M−8.2%558.3K after2 lots10b5-1
Dec 14, 2023 (view filing)Dec 131 dayHessekiel JeffreyEVP, General Counsel & SecSSale−25.0K$23.01−$575.3K−4.5%533.3K after10b5-1
Dec 14, 2023 (view filing)Dec 12-142 daysHaley Patrick J.EVP, CommercialSSale−64.1K$23.16−$1.49M−17.3%307.7K after2 lots10b5-1
Feb 22, 2024 (view filing)5:08 PM ETFeb 211 dayCaligan Partners LP and 1 otherDirector, Other: See RemarksPPurchase+190.0K$20.70+$3.93M+20.9%1.10M after
Feb 27, 2024 (view filing)Feb 234 daysHaley Patrick J.EVP, CommercialSSale−47.0K$21.45−$1.01M−10.9%384.9K after
Mar 25, 2024 (view filing)Mar 214 daysGarber Alan MDirectorSSale−19.2K$24.01−$461.1K−35.0%35.7K after10b5-1
May 15, 2024 (view filing)May 132 daysWyszomierski Jack LDirectorSSale−10.9K$21.37−$233.4K−3.1%338.9K after10b5-1
May 22, 2024 (view filing)May 202 daysPapadopoulos SteliosDirectorSSale−11.4K$21.00−$240.2K−0.9%1.26M after
May 22, 2024 (view filing)May 211 dayPoste GeorgeDirectorSSale−11.7K$20.96−$244.9K−5.2%213.9K after
May 23, 2024 (view filing)May 212 daysSmith JulieDirectorSSale−27.3K$21.12−$576.2K−83.4%5.45K after
May 30, 2024 (view filing)7:50 PM ETMay 28-302 daysCaligan Partners LP and 1 otherDirector, Other: See RemarksPPurchase+425.0K$20.55+$8.73M+38.6%1.53M after2 lots